ORETON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Oreton, and when can generic versions of Oreton launch?
Oreton is a drug marketed by Schering and is included in two NDAs.
The generic ingredient in ORETON is methyltestosterone. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methyltestosterone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oreton
A generic version of ORETON was approved as methyltestosterone by IMPAX LABS on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ORETON?
- What are the global sales for ORETON?
- What is Average Wholesale Price for ORETON?
Summary for ORETON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Patent Applications: | 4,274 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ORETON at DailyMed |
![ORETON drug patent expirations Drug patent expirations by year for ORETON](/p/graph/s/t/ORETON-patent-expirations.png)
US Patents and Regulatory Information for ORETON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Schering | ORETON | methyltestosterone | TABLET;BUCCAL | 080281-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Schering | ORETON METHYL | methyltestosterone | TABLET;ORAL | 003158-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Schering | ORETON METHYL | methyltestosterone | TABLET;ORAL | 003158-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |